VetrixBio today announced preliminary safety and efficacy data from its first in vivo study of VTX-304, the company’s lead program for osteoarthritis in dogs.
The study, conducted in a natural canine model of osteoarthritis, evaluated a single subcutaneous dose across multiple treatment arms. Early results showed meaningful improvements in pain scores over a four-week period, with both variants of VTX-304 demonstrating sustained benefit. The data also support the compound’s tolerability profile, with no unexpected safety findings observed to date.
VTX-304 is a bispecific antibody designed to address both pain signaling and cartilage degredation. While currently available therapies primarily focus on symptom relief, VetrixBio’s approach is intended to extend beyond pain management to potentially the first and only disease-modifying osteoarthritis drug (DMOAD).
“These early data represent an important step in demonstrating the potential of a dual-target approach in osteoarthritis,” said Peter Hanson, Founder and CSO of VetrixBio. “Our goal is to develop therapies that can meaningfully improve outcomes for animals living with chronic degenerative conditions.”
The company plans to continue advancing VTX-304 through additional studies to further characterize dosing, durability, and clinical impact, with full data from the initial study expected in the coming months.
VetrixBio is a biotechnology company focused on developing novel biologic therapies for companion animals. Guided by the belief that pets deserve better medicines, the company is advancing a pipeline targeting osteoarthritis and cancer—two of the most significant unmet needs in veterinary medicine. VetrixBio’s approach centers on translating advances in biologics and immunotherapy into practical treatments designed to improve outcomes and quality of life for dogs and cats. Led by an experienced team spanning biotechnology, animal health, and commercialization, and supported by a network of scientific and clinical advisors, VetrixBio is committed to bringing the next generation of veterinary medicines to market.
VetrixBio, Inc.
47 Enon St., Unit 7, Suite 127
Beverly, MA 01915
info@vetrixbio.com
This press release contains forward-looking statements, including statements regarding the development, potential efficacy, and future progress of VetrixBio’s product candidates. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. VetrixBio undertakes no obligation to update these statements except as required by law.
